Patents Assigned to Kagoshima University
  • Patent number: 11896635
    Abstract: The present invention is based on a novel concept for finding the optimum expression level of a therapeutic gene for inducing the largest therapeutic effect without any adverse reaction. An object of the present invention is to develop an immuno-viral therapeutic vector exerting the optimal therapeutic effect while ensuring high safety. The present invention provides, for example, an oncolytic virus comprising an immunity-inducing gene operably linked to the downstream of E2F promoter or a promoter having an activity equivalent thereto, wherein at least one promoter for nucleic acids encoding an element essential for viral replication or assembly is replaced with a promoter for an organ specific highly expressed factor or with a promoter for a cancer cell specific highly expressed factor.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 13, 2024
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Ken-ichiro Kosai, Nobuhiro Ijichi
  • Patent number: 11873337
    Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 16, 2024
    Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
  • Publication number: 20230414718
    Abstract: An agent for protecting and/or regenerating pancreatic ? cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 28, 2023
    Applicant: KAGOSHIMA UNIVERSITY
    Inventors: Ken-ichiro KOSAI, Eriko MATSUDA
  • Patent number: 11701440
    Abstract: Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: July 18, 2023
    Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL UNIVERSITY CORPORATION KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Shota Komoto, Yu Ogawa, Yoshinari Shoyama, Tadashi Hatano, Yuji Ito, Yasushi Arano, Hiroyuki Suzuki, Tomoya Uehara
  • Publication number: 20230181587
    Abstract: This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: June 15, 2023
    Applicants: KAGOSHIMA UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Takashi KURIHARA, Ichiro TAKASAKI, Hitoshi HASHIMOTO, Atsuko HAYATA, Yusuke SHINTANI
  • Patent number: 11643474
    Abstract: An object of the present invention is to provide a method by which a peptide having a specific binding capability that can be used for purification of a target molecule can be produced at a low cost, and specifically relates to a peptide fusion protein including one or more peptides having specific binding capability and a scaffold protein, the peptide being inserted into the amino acid sequence of the scaffold protein directly or via a peptide linker, and/or being linked to the N-terminal and/or C-terminal of the scaffold protein.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: May 9, 2023
    Assignees: KAGOSHIMA UNIVERSITY, DAICEL CORPORATION
    Inventors: Yuji Ito, Seiichi Uchimura, Hiromichi Okura
  • Patent number: 11583463
    Abstract: A hemiplegic forearm function recovery training device includes a forearm mounting part (2) on which a forearm (S) is to be mounted. The forearm mounting part (2) includes a mounting body (20), an inner frame portion (2B), an outer frame portion (2A), and a control part. The mounting body (20) has a forearm fixing portion (22) on which the forearm (S) is mounted and a gripping mechanism (23) capable of being gripped by a hand of the forearm (S). The inner frame portion (2B) is fitted to the mounting body (20) and is rotatable around the forearm (S). The outer frame portion (2A) guides the inner frame portion (2B) in a rotation direction thereof. The control part performs a series of controls that repeatedly causes normal rotation, stop, reverse rotation, and stop of the inner frame portion (2B) while acquiring rotation angle information of the inner frame portion (2B).
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: February 21, 2023
    Assignees: Kagoshima University, Marumae Co., Ltd.
    Inventors: Yong Yu, Takashi Morimoto, Toshikazu Maeda, Koei Igarashi
  • Patent number: 11571416
    Abstract: Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 7, 2023
    Assignee: Kagoshima University
    Inventors: Robert A. Davey, Yasuteru Sakurai, Masanori Baba, Norikazu Sakakibara
  • Patent number: 11491219
    Abstract: The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 8, 2022
    Assignees: TOKYO YAKUHIN KOGYO CO., LTD., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases, KAGOSHIMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY
    Inventors: Taizou Kamishita, Takashi Miyazaki, Michinori Kohara, Takahiro Sanada, Yoichi Hiasa, Osamu Yoshida, Kyoko Kohara, Hideki Hasegawa
  • Patent number: 11472865
    Abstract: It is an object of the present invention to provide a method for modifying an antibody in a specific and simple manner, and others. The present invention relates to: an IgG-binding peptide, an IgG-binding peptide modified with a crosslinking agent, a complex of an IgG-binding peptide modified with the crosslinking agent and IgG, a method for producing the complex, and others.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 18, 2022
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Patent number: 11473530
    Abstract: A readily combustible portion (110) includes a readily combustible exposed surface (111) that is exposed to a flow channel (CA). A combustion-resistant portion (140), which comprises a material that is more resistant to combustion than the readily combustible portion (110), covers an outer surface of the readily combustible portion (110) on the opposite side from the readily combustible exposed surface (111) in a direction orthogonal to a length direction parallel to a direction in which a hybrid rocket is propelled. The combustion-resistant portion (140) includes a thick portion (120) that serves as a stopper that prevents peeling of the readily combustible portion (110) from the combustion-resistant portion (140) in a direction from a starting end surface (100a) toward a terminating end surface (100b).
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: October 18, 2022
    Assignee: KAGOSHIMA UNIVERSITY
    Inventor: Hiroshi Katanoda
  • Patent number: 11432742
    Abstract: A nasal-cavity model generator (41) extracts pixels having pixel density values within a specific range from three-dimensional image data on a nasal cavity of a subject contained in DICOM data (21), and generates a nasal cavity model (50), which is a three-dimensional model of the nasal cavity, based on three-dimensional image data composed of the extracted pixels. A nasal-cavity resistance calculator (42) calculates a nasal cavity resistance (51) through fluid analysis using the nasal cavity model (50) generated by the nasal-cavity model generator (41). An adjuster (43) adjusts the specific range of the pixel density values of the pixels to be extracted for generation of the nasal cavity model (50) by the nasal-cavity model generator (41) such that the nasal cavity resistance (51) calculated by the nasal-cavity resistance calculator (42) is equal to a nasal cavity resistance (52) actually measured with a nasal-cavity draft gauge.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 6, 2022
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Tomonori Iwasaki, Youichi Yamasaki
  • Patent number: 11365194
    Abstract: This invention relates to an analgesic drug comprising a compound represented by the following formula (I) or (II), wherein R1 is a C1-6-alkoxy group or a C1-6-haloalkoxy group; R2 is a hydrogen atom; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 21, 2022
    Assignees: KAGOSHIMA UNIVERSITY, SHOWA UNIVERSITY
    Inventors: Takashi Kurihara, Ichiro Takasaki, Naoki Toyooka, Hiroaki Gouda
  • Publication number: 20220184081
    Abstract: This invention relates to an antipruritic agent of formula (I) or (II), wherein R1 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; R2 is a hydrogen atom, a C1-6-alkyl group, a C1-6-alkoxy group, a C2-6-alkenyloxy group, a halogen atom, a C1-6-haloalkyl group, a C1-6-haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 16, 2022
    Applicant: KAGOSHIMA UNIVERSITY
    Inventors: Takashi KURIHARA, lchiro TAKASAKl, Naoki TOYOOKA, Hiroaki GOUDA
  • Publication number: 20220152187
    Abstract: The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, KAGOSHIMA UNIVERSITY, NAGASAKI UNIVERSITY
    Inventors: Michinori KOHARA, Fumihiko YASUI, Daisuke YAMANE, Kyoko KOHARA, Kouichi MORITA, Yasuhiro YASUTOMI, Koji ISHII
  • Publication number: 20220033432
    Abstract: The present disclosure aims to provide an anti-hepatitis B virus agent, and a prophylactic or therapeutic agent for a hepatitis B virus-related disease, each comprising a nucleic acid analogue as an active ingredient. The above object can be attained by an anti-hepatitis B virus agent, or a prophylactic or therapeutic agent for a hepatitis B virus-related disease, each comprising, as an active ingredient, a compound represented by the following formula (1): wherein R is a halogen atom, an amino group, a methoxy group, or a cyano group, or its prodrug, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    Type: Application
    Filed: September 13, 2021
    Publication date: February 3, 2022
    Applicants: DAIKIN INDUSTRIES, LTD., KAGOSHIMA UNIVERSITY
    Inventors: Tomohito HAMADA, Hideyuki IKEUCHI, Kanako INOO, Yosuke KISHIKAWA, Masanori IKEDA, Midori TAKEDA
  • Publication number: 20220025044
    Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
    Type: Application
    Filed: August 11, 2021
    Publication date: January 27, 2022
    Applicants: Kyowa Kirin Co., Ltd., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki TAKAHASHI, Ryosuke NAKANO, Sayaka MAEDA, Yuji ITO
  • Publication number: 20220008450
    Abstract: The present disclosure provides an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-related diseases, each comprising a nucleic acid analogue as an active ingredient. The problem can be solved by 2?-deoxy-2?-fluoro-?-2-fluoro-D-adenosine or its prodrug, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 13, 2022
    Applicants: DAIKIN INDUSTRIES, LTD., KAGOSHIMA UNIVERSITY
    Inventors: Tomohito HAMADA, Yosuke KISHIKAWA, Kanako INOO, Masanori IKEDA, Midori TAKEDA
  • Patent number: 11198106
    Abstract: An object of the invention is to provide a method for producing a capsule or microbead having high encapsulation efficiency of an encapsulated substance, high production efficiency, and high versatility. The invention relates to a method for producing a microcapsule or microbead, comprising: a step of disposing a monomer droplet or polymer droplet containing a substance to be encapsulated, which has a surface coated with a plurality of solid fine particles, on a flat surface; and a step of solidifying the monomer droplet or polymer droplet disposed on the flat surface in a gas phase so as to form an outer shell of a capsule or microbead, thereby forming a region enclosed by the outer shell, wherein the substance is encapsulated in the region.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: December 14, 2021
    Assignee: KAGOSHIMA UNIVERSITY
    Inventors: Takayuki Takei, Masahiro Yoshida, Yoshihiro Ohzuno, Gen Hayase
  • Publication number: 20210380637
    Abstract: The purpose of the present invention is to provide a solid-phase carrier on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after IgG purification, and having a high binding affinity for IgG. Specifically, the present invention relates to a solid-phase carrier on which an IgG-binding peptide is immobilized, wherein the two cysteine residues on the outside of the peptide are linked as shown in the following formula: (in the formula, the upper cysteine residue is on the N-terminal side of the peptide, and the lower cysteine residue is on the C-terminal side of the peptide).
    Type: Application
    Filed: October 7, 2019
    Publication date: December 9, 2021
    Applicants: KAGOSHIMA UNIVERSITY, DAICEL CORPORATION
    Inventors: Yuji ITO, Seiichi UCHIMURA